GSK4482820
Phase 1
GSKGSK4482820 is one of 33 therapeutic programs targeting Lupus Nephritis. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
154 competitors in Lupus Nephritis
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Gazyva
RochePhase 3
Orencia
Bristol-Myers SquibbPhase 3
Myfortic
NovartisPhase 3
Arava
SanofiPhase 3
Cosentyx
NovartisPhase 3
Saphnelo
AstraZenecaPhase 3
Rayos
RRoxane Laboratories
Phase 3
Keytruda
Merck & Co.Phase 3
Cellcept
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for GSK4482820. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1
- Company